Starpharma Holdings Limited

Equities

SPL

AU000000SPL0

Pharmaceuticals

Market Closed - Australian S.E. 01:10:10 2024-03-28 am EDT 5-day change 1st Jan Change
0.125 AUD -3.85% Intraday chart for Starpharma Holdings Limited 0.00% -26.47%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Starpharma Holdings Limited(ASX:SPL) dropped from S&P/ASX Emerging Companies Index CI
Starpharma Holdings Limited(ASX:SPL) dropped from S&P/ASX All Ordinaries Index CI
Starpharma Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Starpharma Asked to Provide More Data for US FDA Approval of Vivagel MT
Starpharma Says DEP Docetaxel Shows Positive Results from Clinical Trial MT
Starpharma Presents DEP Platform At Targeted Radiopharmaceuticals Conference in Berlin MT
Starpharma Names CEO MT
Starpharma Holdings Limited Appoints Cheryl Maley as Managing Director, Effective 8 January 2024 CI
Starpharma Holdings Limited Appoints Cheryl Maley as Chief Executive Officer, Effective 8 January 2024 CI
Starpharma Secures AU$7 Million Tax Rebate for Fiscal Year 2023; Shares Rise 4% MT
Starpharma's Anti-Prostate Cancer Medication Shows Efficacy in Phase 2 Trials MT
Starpharma Presents DEP Irinotecan Clinical Data at AACR Meeting; Shares Jump 7% MT
Starpharma Completes Enrollment for COVID-19 Study MT
Starpharma Holdings Limited Announces Viraleze for Respiratory and Cold Viruses CI
Starpharma Holdings Limited(ASX:SPL) dropped from S&P Global BMI Index CI
Starpharma Holdings Limited Announces Change of Company Secretary CI
Starpharma Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Starpharma Radiodiagnostic Candidate Shows Imaging Benefits in Study; Shares Jump 8% MT
Starpharma CEO to Retire in 2024 MT
Starpharma Announces Resignation of Jackie Fairley as Chief Executive Officer CI
Starpharma's Viraleze Antiviral Nasal Spray Approved in Malaysia MT
Starpharma CFO Starts in Role MT
Starpharma Holdings Limited Appoints Justin Cahill as Company Secretary CI
Starpharma Appoints CFO MT
Starpharma Holdings Limited Appoints Justin Cahill as Chief Financial Officer CI
Chart Starpharma Holdings Limited
More charts
Starpharma Holdings Limited is an Australia-based biopharmaceutical company. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical, life-science and other applications. It is focused on developing and commercializing novel therapeutic products that address global healthcare needs. The Company is also involved in the development of nano-scale materials, including the development of VivaGel for the management and prevention of bacterial vaginosis, and as an antiviral condom coating, and VIRALEZE, an antiviral nasal spray. The Company is also applying its proprietary dendrimers to drug delivery to create improved pharmaceuticals and has developed the valuable DEP delivery platform. VIRALEZE is a broad-spectrum nasal spray intended to provide a moisturizing and protective barrier in the nose that traps and blocks cold/respiratory viruses. It also offers VivaGel BV and VivaGel Condom products.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Starpharma Holdings Limited - Australian S.E.
  4. News Starpharma Holdings Limited
  5. Starpharma : Posts 34% Wider Loss in FY21 on Absence of One-Off Payments